Literature DB >> 18572325

Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis.

K Mitosek-Szewczyk1, G Sulkowski, Z Stelmasiak, L Struzyńska.   

Abstract

Demyelination and oligodendroglial cell death accompanied by axonal injury are dominating features of multiple sclerosis (MS) a chronic demyelinating disease of the CNS. Accumulation of extracellular glutamate, observed during MS, is implicated in excitotoxic injury of nerve and oligodendroglial cells as a result of over-activation of glutamate receptors. The appropriate concentration of extracellular glutamate is maintained by glutamate transporters, the most predominant of which is glial transporter GLT-1 (excitatory amino acid transporter (EAAT) 2). The aim of this study is to determine the time-course of GLT-1 and glutamate-aspartate transporter (GLAST) expression in forebrain and cerebellum of rats subjected to experimental autoimmune encephalomyelitis (EAE). Our findings revealed that: (1) GLT-1 mRNA and to a lower extent GLAST mRNA are overexpressed in forebrain and cerebellum of EAE rats (2) expression of GLT-1 transporter mRNA shows a similar temporal pattern throughout the course of EAE in both structures examined, and is closely correlated with the appearance of neurological symptoms; and (3) the expression of GLT-1 and GLAST protein does not mirror mRNA changes during EAE and exhibits a differential spatial pattern. The protein levels of GLT-1 in cerebellum and GLAST in both structures are significantly reduced just before the acute phase and later during the recovery. The results imply that transcriptional up-regulation of the GLT-1 gene occurs early in both the forebrain and the cerebellum of the EAE rat model. This up-regulation is associated with the severity of symptoms but tends to precede the onset of maximal neurological deficits. The observations confirm the involvement of glutamate in the pathogenesis of EAE and provide an indication of the protective role of this glutamate transporter. However, changes in protein expression of both transporters suggest the existence of post-translational disturbances or the influence of regulating factors connecting with EAE conditions that may lead to the insufficient protection against glutamate excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572325     DOI: 10.1016/j.neuroscience.2008.05.025

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  16 in total

1.  Adenosine Monophosphate-activated Protein Kinase Regulates Interleukin-1β Expression and Glial Glutamate Transporter Function in Rodents with Neuropathic Pain.

Authors:  Dylan W Maixner; Xisheng Yan; Mei Gao; Ruchi Yadav; Han-Rong Weng
Journal:  Anesthesiology       Date:  2015-06       Impact factor: 7.892

2.  Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.

Authors:  Georgia Mandolesi; Alessandra Musella; Antonietta Gentile; Giorgio Grasselli; Nabila Haji; Helena Sepman; Diego Fresegna; Silvia Bullitta; Francesca De Vito; Gabriele Musumeci; Claudio Di Sanza; Piergiorgio Strata; Diego Centonze
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

3.  Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

Authors:  Chien-Liang Glenn Lin; Qiongman Kong; Gregory D Cuny; Marcie A Glicksman
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

4.  Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum.

Authors:  Angela Groebe; Tim Clarner; Werner Baumgartner; Jon Dang; Cordian Beyer; Markus Kipp
Journal:  Cerebellum       Date:  2009-03-04       Impact factor: 3.847

Review 5.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.

Authors:  Georgia Mandolesi; Antonietta Gentile; Alessandra Musella; Diego Fresegna; Francesca De Vito; Silvia Bullitta; Helena Sepman; Girolama A Marfia; Diego Centonze
Journal:  Nat Rev Neurol       Date:  2015-11-20       Impact factor: 42.937

6.  The chemokine, macrophage inflammatory protein-2γ, reduces the expression of glutamate transporter-1 on astrocytes and increases neuronal sensitivity to glutamate excitotoxicity.

Authors:  Jie Fang; Deping Han; Jinsheng Hong; Qi Tan; Yeping Tian
Journal:  J Neuroinflammation       Date:  2012-12-12       Impact factor: 8.322

7.  Modulation of glutamate transport and receptor binding by glutamate receptor antagonists in EAE rat brain.

Authors:  Grzegorz Sulkowski; Beata Dąbrowska-Bouta; Elżbieta Salińska; Lidia Strużyńska
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

8.  Absence of system xc- on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis.

Authors:  Ellen Merckx; Giulia Albertini; Magdalena Paterka; Cathy Jensen; Philipp Albrecht; Michael Dietrich; Joeri Van Liefferinge; Eduard Bentea; Lise Verbruggen; Thomas Demuyser; Lauren Deneyer; Jan Lewerenz; Geert van Loo; Jacques De Keyser; Hideyo Sato; Pamela Maher; Axel Methner; Ann Massie
Journal:  J Neuroinflammation       Date:  2017-01-13       Impact factor: 8.322

Review 9.  Astrocyte phenotypes: Emphasis on potential markers in neuroinflammation.

Authors:  Iva Bozic; Danijela Savic; Irena Lavrnja
Journal:  Histol Histopathol       Date:  2020-11-23       Impact factor: 2.303

10.  Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors.

Authors:  Grzegorz Sulkowski; Beata Dąbrowska-Bouta; Lidia Strużyńska
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.